ClinicalTrials.gg
CompletedNCT05560646ELENAUpdated May 8, 2026Results posted

A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

A Phase 2 interventional study of OG-6219 and Placebo in Endometriosis, sponsored by Organon and Co. Completed at 86 sites in 11 countries. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Organon and Co · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
354
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 169 studies in Endometriosis with a site in United States — 38 open to participants now, 48 under way, 5 of them phase 3. Endometriosis · United States.

Enrollment
12th of 131
354 · median 60
Started
2022
with 14 others
Phase 2
39 of 169
1 open now
Registered
123rd of 169
by date

Among the 169 studies in Endometriosis with a site in United States, this one is the 12th largest by enrollment of the 131 interventional ones that give a count, is one of 15 that started in 2022, is one of 39 in phase 2, and was the 123rd registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

38 of the 169 studies in Endometriosis with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 49 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 169 studies in Endometriosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.

Read the detailed description

This is a global multicenter, Phase 2a/b, randomized, double-blind, Placebo-controlled study to assess the efficacy, safety, and tolerability of 3 dose levels of OG-6219, in pre-menopausal women 18 to 49 years of age (inclusive), who have been surgically diagnosed with endometriosis with moderate to severe endometriosis-related pain. This study includes treatment lasting approximately 16 weeks in total and is followed by a Safety Follow-up visit.

Pre-menopausal females aged 18 to 49 years old (inclusive), who have been surgically diagnosed with endometriosis will be screened and randomly assigned to study treatment. A minimum subset of 10 participants per treatment group (including Placebo group) will be voluntarily enrolled for optional intensive PK sampling for the entire duration of the study.

03

Conditions studied

  • Endometriosis

Browse trials for

Keywords

  • Endometriosis Related Pain (ERP)
  • Endometriosis
  • Pre-menopausal women
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pre-menopausal females of age 18 to 49 years old (inclusive) at the time of signing (V1).
  • Surgically (laparoscopy or laparotomy) diagnosed with endometriosis
  • Moderate to severe endometriosis-related pelvic pain
  • Regular menstrual cycles
  • Is not expected to undergo a planned gynecological surgery or other surgical procedures for treatment of endometriosis during study participation.
  • Normal breast exam at V1. In participants of ≥40 years mammography or contrast-enhanced breast MRI performed within the last 12 months prior to Screening (V1) without abnormal findings.
  • Agree not to participate in another interventional study while participating in the present study.
  • Able and willing to adhere to study procedures, including
  • agree to use 2 forms of non-hormonal throughout the study
  • Must be willing and able to provide signed informed consent before any study-related activities
  • Has demonstrated compliance with ≥75% of eDiary entries
  • Has a negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Surgical history of hysterectomy and/or bilateral oophorectomy
  • Chronic pelvic and/or non-pelvic pain not caused by endometriosis that requires chronic analgesic or other chronic therapy
  • Undiagnosed (unexplained), abnormal vaginal bleeding not associated with endometriosis within the past 6 months before screening.
  • Presence of high-risk human papillomavirus (HPV).
  • Has an active sexually transmitted infection (STI) (eg, gonorrhea, chlamydia, or trichomonas).
  • Intends to become pregnant or breast feed during study participation or has a known or suspected pregnancy.
  • History of (except for basal cell or squamous cell skin cancer) before signing .
  • History of family history of hereditary abnormal or an enzyme deficiency that can result in methemoglobinemia.
  • Has a medical condition associated with hemolytic anemia
  • Known infection, and/or acute or active, recurrent/relapsing, or chronic infection (eg, hepatitis A, B, or C virus)
  • Has a abnormal or prolongation
  • Used any medication that is either a sensitive substrate, moderate, or strong inhibitor or inducer of within 30 days or 10 half-lives (whichever is longer) prior to the planned first day of dosing.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
354 participants (actual)

Study arms

  • Experimental
    Group A: OG-6219 Dose 1

    Group A: OG-6219 Dose 1 BID

    Drug: OG-6219

  • Experimental
    Group B: OG-6219 Dose 2

    Group B: OG-6219 Dose 2 BID

    Drug: OG-6219

  • Experimental
    Group C: OG-6219 Dose 3

    Group C: OG-6219 Dose 3 BID

    Drug: OG-6219

  • Placebo comparator
    Group D: Placebo

    Group D: Placebo BID

    Drug: Placebo

Interventions

  • DrugLinustedastatStudies of LinustedastatLinustedastat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    OG-6219 Dose 1, Dose 2, Dose 3 BID: Participants will receive (orally) OG-6219 tablets during treatment cycles.

  • DrugPlacebo

    Participants will receive (orally) OG-6219 Placebo tablets BID during treatment cycles.

06

What researchers measure

Primary outcomes

  1. Change From Baseline Cycle in Mean Overall Pelvic Pain Score at Treatment Cycle 3

    Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dysmenorrhea or NMPP, and dyspareunia. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean OPP score was derived by the pain score for the dysmenorrhea and NMPP items, and score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. Baseline cycle OPP score was defined as the average daily OPP during baseline cycle.

    Time frame: Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  2. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant administered an investigational product and which does not necessarily have a causal relationship with this treatment. An SAE was defined as any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. TEAEs were defined as events that first occur or worsen (increase in severity) after the first dose of study drug, during the treatment period, and up to 14 days (inclusive) after the last dose of study drug administration. Percentages are rounded off to the hundredth decimal place.

    Time frame: From the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days

  3. Percentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation

    An AE was defined as any untoward medical occurrence in a clinical study participant administered an investigational product and which does not necessarily have a causal relationship with this treatment. TEAEs were defined as events that first occur or worsen (increase in severity) after the first dose of study drug, during the treatment period, and up to 14 days (inclusive) after the last dose of study drug administration. The TEAEs leading to permanent discontinuation of study drug was identified by using the 'Action taken with study treatment' variable equal to 'Drug withdrawal' from the AE page of the electronic case report form. Percentages are rounded off to the hundredth decimal place.

    Time frame: From the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days

Secondary outcomes

  1. Change From Baseline Cycle in Mean Dysmenorrhea Score at Treatment Cycle 3

    Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dysmenorrhea. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean dysmenorrhea score was calculated for each cycle as the total of daily dysmenorrhea scores reported during the cycle divided by the number of days during the cycle when a dysmenorrhea score was reported. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.

    Time frame: Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  2. Change From Baseline Cycle in Mean Non-Menstrual Pelvic Pain Score at Treatment Cycle 3

    Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dysmenorrhea. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean NMPP score was calculated for each cycle as the total of daily NMPP scores reported during the cycle divided by the number of days during the cycle when a NMPP score was reported. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.

    Time frame: Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  3. Change From Baseline Cycle in Mean Dyspareunia Score at Treatment Cycle 3

    Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dyspareunia. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean dyspareunia score was calculated for each cycle as the total of dyspareunia scores reported during each cycle divided by the number of days when participants engaged in any sexual activity that involved full vaginal penetration during each cycle (that is, the number of days during the baseline cycle when a dyspareunia score was reported). Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.

    Time frame: Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  4. Change From Baseline Cycle in Mean Number of Rescue Medication Tablets Used for Endometriosis-Related Pain at Treatment Cycles 1, 2 and 3

    Participants were asked daily whether they used the rescue medication in the past 24 hours to treat their ERP. If yes, the number of tablets was documented. The mean number of tablets of rescue medication for ERP was calculated for each cycle as the total number of tablets of rescue medication for ERP reported during the cycle, divided by the number of days during the cycle when a value was reported. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.

    Time frame: Baseline Cycle (up to Day -28) and Treatment Cycles 1 (Day 32), 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  5. Change From Baseline Cycle in Percentage of Days With Participants Used Rescue Medication for Endometriosis-Related Pain at Treatment Cycles 1, 2 and 3

    Participants were asked daily whether they used the rescue medication in the past 24 hours to treat their ERP. If yes, the number of tablets was documented. The percentage of days participant had used rescue medication for ERP was calculated for each cycle as the total number of days participant had used any rescue medication for ERP, divided by the number of days during the cycle when a value was reported. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.

    Time frame: Baseline Cycle (up to Day -28) and Treatment Cycles 1 (Day 32), 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  6. Change From Start of Treatment Cycle 1 in Participants With Patient Global Impression of Severity (PGI-S) to Start of Treatment Cycle 2, End of Treatment Cycles 2 and 3

    The PGI-S was a single item measuring the overall severity of pelvic pain over the past 7 days on a 4-point Likert-type scale (0=None, 1=Mild, 2=Moderate, 3=Severe), score ranged from 0 (none) and 3 (severe), where lower score indicated a better outcome. Treatment Cycle 1 was the period between the first day of menses associated with treatment start (Visit 4) to the day prior to the first day of next menses, regardless of number of days.

    Time frame: Start of Treatment Cycle 1 (Day 1) and start of Treatment Cycle 2 (Day 33), end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  7. Percentage of Participants With Any Improvement on the Patient Global Impression of Change (PGI-C) at Start of Treatment Cycle 2 and End of Treatment Cycles 2 and 3

    The PGI-C was a single item measuring the change in pelvic pain since the start of the study drug on a 5-point scale (0=much better, 1=a little better, 2=no change, 3=a little worse, 4=much worse), score ranged from 0 (much better) and 4 (much worse), where lower score indicated a better outcome. Participants with any improvement on the PGI-C were defined as a PGI-C score of 0 or 1 (0=much better and 1=a little better). Treatment Cycle 2 was the period between the first day of menses associated with start of treatment Cycle 2 to the day prior to the first day of next menses, regardless of number of days.

    Time frame: Start of Treatment Cycle 2 (Day 33), end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  8. Change From Baseline Cycle in Endometriosis Health Profile-30 (EHP-30) Domains Score at Treatment Cycle 3

    The EHP-30 was a validated disease specific patient-reported outcome instrument measuring the health-related quality of life of women with endometriosis on a 5-point Likert-type scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=always). The EHP-30 consisted of 30 items with following domains: pain (11 items), score ranged from 0 (never) to 44 (always); controls and powerlessness (6 items), score ranged from 0 (never) to 24 (always); emotional well-being (6 items), score ranged from 0 (never) to 24 (always); social support (4 items), score ranged from 0 (never) to 16 (always); and self-image (3 items), score ranged from 0 (never) to 12 (always). Each domain lower score indicated a better outcome. Total EHP-30 score ranged from 0 (never) and 120 (always), where lower score indicated a better outcome. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.

    Time frame: Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  9. Mean Change From Screening in C-Telopeptide of Type I Collagen (CTX) and Procollagen Type I N-Terminal Propeptide (P1NP) at End of Treatment Cycle 3

    Potential effects on bone was monitored by biomarkers of bone resorption and formation. Bone resorption was determined by assessing CTX level and bone formation was determined by assessing P1NP level. Screening (Visit 1) was defined as the last measurement before study drug administration.

    Time frame: Screening visit (Day -84) and end of Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  10. Mean Change From Screening in Bone-Specific Alkaline Phosphatase (BSAP) and Osteocalcin at End of Treatment Cycle 3

    Potential effects on bone was monitored by biomarkers of bone resorption and formation. Bone formation was determined by assessing BSAP and osteocalcin level. Screening (Visit 1) was defined as the last measurement before study drug administration.

    Time frame: Screening visit (Day -84) and end of Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  11. Mean Change From Screening in N-Telopeptide of Type I Collagen (NTX) at End of Treatment Cycle 3

    Potential effects on bone was monitored by biomarkers of bone resorption and formation. Bone resorption was determined by assessing NTX level. Screening (Visit 1) was defined as the last measurement before study drug administration. nmol BCE/L= nanomoles of bone collagen equivalents per liter.

    Time frame: Screening visit (Day -84) and end of Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  12. Mean Change From Screening in Tartrate-Resistant Acid Phosphatase 5b (TRAP5b) at End of Treatment Cycle 3

    Potential effects on bone was monitored by biomarkers of bone resorption and formation. Bone resorption was determined by assessing TRAP5b level. Screening (Visit 1) was defined as the last measurement before study drug administration.

    Time frame: Screening visit (Day -84) and end of Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  13. Number of Participants With Clinically Significant Laboratory Abnormalities

    Blood samples were collected to determine the clinical laboratory abnormalities. The laboratory assessments included chemistry, hematology and urinalysis.

    Time frame: From the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days

  14. Mean Change From Baseline Cycle in Sum of Days on Period at Treatment Cycles 1, 2 and 3

    Participants recorded the presence of bleeding or spotting daily in the eDiary. The daily questions to assess bleeding pattern in the eDiary were "1a: During the past 24 hours, did you have any vaginal bleeding or spotting? If the response is "Yes", then the next question is, "1b: During the past 24 hours, have you been on your period?". Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.

    Time frame: Baseline Cycle (up to Day -28) and Treatment Cycles 1 (Day 32), 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  15. Number of Participants With Clinically Significant Electrocardiogram (ECG) Parameters Abnormalities

    Triplicate standard 12-lead ECGs was obtained after the participant was in supine position for at least 5 minutes. The ECG measurements was summarized by taking the average of the available assessments. Only clinically significant ECG abnormalities are reported.

    Time frame: From the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days

  16. Mean Change From Screening in Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3

    Blood samples were collected to determine the serum level of LH and FSH. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.

    Time frame: Screening visit (Day -84) and 7 days after urine LH surge, end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  17. Mean Change From Screening in Estrone (E1) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3

    Blood samples were collected to determine the serum level of E1. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.

    Time frame: Screening visit (Day -84) and 7 days after urine LH surge, end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  18. Mean Change From Screening in Progesterone, Testosterone and Dehydroepiandrosterone (DHEA) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3

    Blood samples were collected to determine the serum level of progesterone, testosterone and DHEA. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.

    Time frame: Screening visit (Day -84) and 7 days after urine LH surge, end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  19. Mean Change From Screening in Free Testosterone and Estradiol (E2) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3

    Blood samples were collected to determine the serum level of free testosterone and E2. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.

    Time frame: Screening visit (Day -84) and 7 days after urine LH surge, end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  20. Mean Change From Screening in Dehydroepiandrosterone Sulfate (DHEAS) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3

    Blood samples were collected to determine the serum level of DHEAS. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.

    Time frame: Screening visit (Day -84) and 7 days after urine LH surge, end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).

  21. Plasma Concentrations of OG-6219 and FOR-1011

    Blood samples were collected to determine plasma concentration of OG-6219 and FOR-1011. The plasma concentration of OG-6219 and FOR-1011 was analyzed using an appropriate validated bioanalytical method.

    Time frame: Pre-witness dose and 1.5 hours postdose on start of Treatment Cycle 1 (Day 1), at 7 days after urine LH surge, and end of Treatment Cycle 2; Pre-witness dose on end of Treatment Cycle 3

  22. Maximum Concentration (Cmax) of OG-6219 and FOR-1011

    Blood samples were collected to determine Cmax of OG-6219 and FOR-1011. The Cmax of OG-6219 and FOR-1011 was calculated using non-compartmental method. NCA= Noncompartmental analysis.

    Time frame: Pre-witness dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose on start of Treatment Cycle 1 (Day 1) and at 7 days after urine LH surge

  23. Time Taken to Reach the Maximum Concentration (Tmax) of OG-6219 and FOR-1011

    Blood samples were collected to determine tmax of OG-6219 and FOR-1011. The tmax of OG-6219 and FOR-1011 was calculated using non-compartmental method.

    Time frame: Pre-witness dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose on start of Treatment Cycle 1 (Day 1) and at 7 days after urine LH surge

  24. Area Under the Plasma Concentration-Time Curve During a Dosing Interval (AUCtau) of OG-6219 and FOR-1011

    Blood samples were collected to determine AUCtau of OG-6219 and FOR-1011. The AUCtau of OG-6219 and FOR-1011 was calculated using non-compartmental method.

    Time frame: Pre-witness dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose on start of Treatment Cycle 1 (Day 1) and at 7 days after urine LH surge

07

Results

Posted May 8, 2026

Participant flow

This Phase 2a/b, double-blind, placebo-controlled study was conducted in pre-menopausal women 18 to 49 years of age with moderate to severe endometriosis-related pain (ERP) at 93 centers in 11 countries between 25 October 2022 and 28 May 2025.

Participant flow — Overall Study
MilestonePlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Started88898889
Completed78788178
Not completed1011711
Withdrew: Adverse event3204
Withdrew: Lack of efficacy0110
Withdrew: Lost to follow-up2111
Withdrew: Non-compliance with study drug1001
Withdrew: Physician decision0001
Withdrew: Pregnancy0021
Withdrew: Protocol violation0102
Withdrew: Withdrawal by subject1411
Withdrew: Other3220

Outcome measures

PrimaryChange From Baseline Cycle in Mean Overall Pelvic Pain Score at Treatment Cycle 3

Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dysmenorrhea or NMPP, and dyspareunia. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean OPP score was derived by the pain score for the dysmenorrhea and NMPP items, and score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. Baseline cycle OPP score was defined as the average daily OPP during baseline cycle.

Time frame:
Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · score on a scale
Change From Baseline Cycle in Mean Overall Pelvic Pain Score at Treatment Cycle 3
score on a scalePlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Change From Baseline Cycle in Mean Overall Pelvic Pain Score at Treatment Cycle 3-1.8 ± 1.94-1.6 ± 1.86-1.5 ± 1.80-2.0 ± 2.12
PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant administered an investigational product and which does not necessarily have a causal relationship with this treatment. An SAE was defined as any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. TEAEs were defined as events that first occur or worsen (increase in severity) after the first dose of study drug, during the treatment period, and up to 14 days (inclusive) after the last dose of study drug administration. Percentages are rounded off to the hundredth decimal place.

Time frame:
From the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
percentage of participantsPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Any TEAE51.152.351.155.1
Any TESAE01.100
PrimaryPercentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation

An AE was defined as any untoward medical occurrence in a clinical study participant administered an investigational product and which does not necessarily have a causal relationship with this treatment. TEAEs were defined as events that first occur or worsen (increase in severity) after the first dose of study drug, during the treatment period, and up to 14 days (inclusive) after the last dose of study drug administration. The TEAEs leading to permanent discontinuation of study drug was identified by using the 'Action taken with study treatment' variable equal to 'Drug withdrawal' from the AE page of the electronic case report form. Percentages are rounded off to the hundredth decimal place.

Time frame:
From the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation
percentage of participantsPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Percentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation3.42.31.15.6
SecondaryChange From Baseline Cycle in Mean Dysmenorrhea Score at Treatment Cycle 3

Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dysmenorrhea. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean dysmenorrhea score was calculated for each cycle as the total of daily dysmenorrhea scores reported during the cycle divided by the number of days during the cycle when a dysmenorrhea score was reported. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.

Time frame:
Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · score on a scale
Change From Baseline Cycle in Mean Dysmenorrhea Score at Treatment Cycle 3
score on a scalePlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Change From Baseline Cycle in Mean Dysmenorrhea Score at Treatment Cycle 3-1.9 ± 2.23-1.5 ± 1.94-1.5 ± 2.16-1.9 ± 2.29
SecondaryChange From Baseline Cycle in Mean Non-Menstrual Pelvic Pain Score at Treatment Cycle 3

Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dysmenorrhea. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean NMPP score was calculated for each cycle as the total of daily NMPP scores reported during the cycle divided by the number of days during the cycle when a NMPP score was reported. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.

Time frame:
Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · score on a scale
Change From Baseline Cycle in Mean Non-Menstrual Pelvic Pain Score at Treatment Cycle 3
score on a scalePlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Change From Baseline Cycle in Mean Non-Menstrual Pelvic Pain Score at Treatment Cycle 3-1.9 ± 2.03-1.6 ± 2.03-1.5 ± 1.86-2.1 ± 2.24
SecondaryChange From Baseline Cycle in Mean Dyspareunia Score at Treatment Cycle 3

Participants completed eDiary items for severity of their pain over the last 24 hours on 11-point NRS for dyspareunia. Each item of the NRS pain severity score ranged from 0 (no pain) to 10 (worst pain imaginable), where lower score indicated a better outcome. The mean dyspareunia score was calculated for each cycle as the total of dyspareunia scores reported during each cycle divided by the number of days when participants engaged in any sexual activity that involved full vaginal penetration during each cycle (that is, the number of days during the baseline cycle when a dyspareunia score was reported). Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.

Time frame:
Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · score on a scale
Change From Baseline Cycle in Mean Dyspareunia Score at Treatment Cycle 3
score on a scalePlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Change From Baseline Cycle in Mean Dyspareunia Score at Treatment Cycle 3-1.5 ± 2.32-1.3 ± 2.11-1.5 ± 2.21-1.2 ± 2.61
SecondaryChange From Baseline Cycle in Mean Number of Rescue Medication Tablets Used for Endometriosis-Related Pain at Treatment Cycles 1, 2 and 3

Participants were asked daily whether they used the rescue medication in the past 24 hours to treat their ERP. If yes, the number of tablets was documented. The mean number of tablets of rescue medication for ERP was calculated for each cycle as the total number of tablets of rescue medication for ERP reported during the cycle, divided by the number of days during the cycle when a value was reported. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.

Time frame:
Baseline Cycle (up to Day -28) and Treatment Cycles 1 (Day 32), 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · mean number of tablets
Change From Baseline Cycle in Mean Number of Rescue Medication Tablets Used for Endometriosis-Related Pain at Treatment Cycles 1, 2 and 3
mean number of tabletsPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Treatment Cycle 1-0.2 ± 0.38-0.2 ± 0.44-0.2 ± 0.46-0.2 ± 0.42
Treatment Cycle 2-0.2 ± 0.55-0.2 ± 0.43-0.2 ± 0.39-0.2 ± 0.50
Treatment Cycle 3-0.3 ± 0.54-0.3 ± 0.47-0.3 ± 0.55-0.2 ± 0.58
SecondaryChange From Baseline Cycle in Percentage of Days With Participants Used Rescue Medication for Endometriosis-Related Pain at Treatment Cycles 1, 2 and 3

Participants were asked daily whether they used the rescue medication in the past 24 hours to treat their ERP. If yes, the number of tablets was documented. The percentage of days participant had used rescue medication for ERP was calculated for each cycle as the total number of days participant had used any rescue medication for ERP, divided by the number of days during the cycle when a value was reported. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.

Time frame:
Baseline Cycle (up to Day -28) and Treatment Cycles 1 (Day 32), 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · percentage of days
Change From Baseline Cycle in Percentage of Days With Participants Used Rescue Medication for Endometriosis-Related Pain at Treatment Cycles 1, 2 and 3
percentage of daysPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Treatment Cycle 1-10.7 ± 21.42-8.7 ± 18.40-9.2 ± 19.23-14.1 ± 21.12
Treatment Cycle 2-15.6 ± 27.95-9.8 ± 16.97-10.2 ± 19.42-15.9 ± 25.11
Treatment Cycle 3-18.7 ± 28.52-13.2 ± 19.04-14.2 ± 24.17-16.4 ± 29.04
SecondaryChange From Start of Treatment Cycle 1 in Participants With Patient Global Impression of Severity (PGI-S) to Start of Treatment Cycle 2, End of Treatment Cycles 2 and 3

The PGI-S was a single item measuring the overall severity of pelvic pain over the past 7 days on a 4-point Likert-type scale (0=None, 1=Mild, 2=Moderate, 3=Severe), score ranged from 0 (none) and 3 (severe), where lower score indicated a better outcome. Treatment Cycle 1 was the period between the first day of menses associated with treatment start (Visit 4) to the day prior to the first day of next menses, regardless of number of days.

Time frame:
Start of Treatment Cycle 1 (Day 1) and start of Treatment Cycle 2 (Day 33), end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Count of participants · Participants
Change From Start of Treatment Cycle 1 in Participants With Patient Global Impression of Severity (PGI-S) to Start of Treatment Cycle 2, End of Treatment Cycles 2 and 3
ParticipantsPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Start of Treatment Cycle 2 — None4367
Start of Treatment Cycle 2 — Mild23171217
Start of Treatment Cycle 2 — Moderate35383939
Start of Treatment Cycle 2 — Severe23232521
End of Treatment Cycle 2 — None3296
End of Treatment Cycle 2 — Mild24211821
End of Treatment Cycle 2 — Moderate36353132
End of Treatment Cycle 2 — Severe17212421
End of Treatment Cycle 3 — None671217
End of Treatment Cycle 3 — Mild27241726
End of Treatment Cycle 3 — Moderate29293620
End of Treatment Cycle 3 — Severe17171515
SecondaryPercentage of Participants With Any Improvement on the Patient Global Impression of Change (PGI-C) at Start of Treatment Cycle 2 and End of Treatment Cycles 2 and 3

The PGI-C was a single item measuring the change in pelvic pain since the start of the study drug on a 5-point scale (0=much better, 1=a little better, 2=no change, 3=a little worse, 4=much worse), score ranged from 0 (much better) and 4 (much worse), where lower score indicated a better outcome. Participants with any improvement on the PGI-C were defined as a PGI-C score of 0 or 1 (0=much better and 1=a little better). Treatment Cycle 2 was the period between the first day of menses associated with start of treatment Cycle 2 to the day prior to the first day of next menses, regardless of number of days.

Time frame:
Start of Treatment Cycle 2 (Day 33), end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Number · percentage of participants
Percentage of Participants With Any Improvement on the Patient Global Impression of Change (PGI-C) at Start of Treatment Cycle 2 and End of Treatment Cycles 2 and 3
percentage of participantsPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Start of Treatment Cycle 256.860.251.161.8
End of Treatment Cycle 262.564.862.566.3
End of Treatment Cycle 365.960.264.866.3
SecondaryChange From Baseline Cycle in Endometriosis Health Profile-30 (EHP-30) Domains Score at Treatment Cycle 3

The EHP-30 was a validated disease specific patient-reported outcome instrument measuring the health-related quality of life of women with endometriosis on a 5-point Likert-type scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=always). The EHP-30 consisted of 30 items with following domains: pain (11 items), score ranged from 0 (never) to 44 (always); controls and powerlessness (6 items), score ranged from 0 (never) to 24 (always); emotional well-being (6 items), score ranged from 0 (never) to 24 (always); social support (4 items), score ranged from 0 (never) to 16 (always); and self-image (3 items), score ranged from 0 (never) to 12 (always). Each domain lower score indicated a better outcome. Total EHP-30 score ranged from 0 (never) and 120 (always), where lower score indicated a better outcome. Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.

Time frame:
Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · score on a scale
Change From Baseline Cycle in Endometriosis Health Profile-30 (EHP-30) Domains Score at Treatment Cycle 3
score on a scalePlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Pain Scale Score-21.04 ± 18.714-20.96 ± 19.753-19.75 ± 19.016-24.62 ± 24.276
Controls and Powerlessness Scale Score-23.93 ± 26.747-22.75 ± 23.780-18.61 ± 27.319-28.58 ± 30.104
Emotional Well-Being Scale Score-17.41 ± 18.667-16.78 ± 21.322-12.07 ± 20.103-17.09 ± 23.229
Social Support Scale Score-18.43 ± 23.470-17.11 ± 23.170-9.01 ± 25.719-19.71 ± 29.073
Self-Image Scale Score-15.60 ± 23.736-14.91 ± 22.498-14.61 ± 23.027-14.74 ± 27.324
SecondaryMean Change From Screening in C-Telopeptide of Type I Collagen (CTX) and Procollagen Type I N-Terminal Propeptide (P1NP) at End of Treatment Cycle 3

Potential effects on bone was monitored by biomarkers of bone resorption and formation. Bone resorption was determined by assessing CTX level and bone formation was determined by assessing P1NP level. Screening (Visit 1) was defined as the last measurement before study drug administration.

Time frame:
Screening visit (Day -84) and end of Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · nanogram per milliliter (ng/mL)
Mean Change From Screening in C-Telopeptide of Type I Collagen (CTX) and Procollagen Type I N-Terminal Propeptide (P1NP) at End of Treatment Cycle 3
nanogram per milliliter (ng/mL)PlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
CTX0.0 ± 0.120.0 ± 0.140.0 ± 0.160.0 ± 0.16
P1NP2.3 ± 15.68-1.7 ± 12.66-0.2 ± 17.90-3.6 ± 14.39
SecondaryMean Change From Screening in Bone-Specific Alkaline Phosphatase (BSAP) and Osteocalcin at End of Treatment Cycle 3

Potential effects on bone was monitored by biomarkers of bone resorption and formation. Bone formation was determined by assessing BSAP and osteocalcin level. Screening (Visit 1) was defined as the last measurement before study drug administration.

Time frame:
Screening visit (Day -84) and end of Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · microgram per liter
Mean Change From Screening in Bone-Specific Alkaline Phosphatase (BSAP) and Osteocalcin at End of Treatment Cycle 3
microgram per literPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
BSAP0.3 ± 2.00-0.7 ± 2.00-0.1 ± 2.52-0.5 ± 1.83
Osteocalcin0.8 ± 4.72-0.8 ± 3.69-0.6 ± 5.28-1.5 ± 4.08
SecondaryMean Change From Screening in N-Telopeptide of Type I Collagen (NTX) at End of Treatment Cycle 3

Potential effects on bone was monitored by biomarkers of bone resorption and formation. Bone resorption was determined by assessing NTX level. Screening (Visit 1) was defined as the last measurement before study drug administration. nmol BCE/L= nanomoles of bone collagen equivalents per liter.

Time frame:
Screening visit (Day -84) and end of Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · nmol BCE/L
Mean Change From Screening in N-Telopeptide of Type I Collagen (NTX) at End of Treatment Cycle 3
nmol BCE/LPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Mean Change From Screening in N-Telopeptide of Type I Collagen (NTX) at End of Treatment Cycle 329.8 ± 421.1528.2 ± 268.191.7 ± 398.939.0 ± 386.61
SecondaryMean Change From Screening in Tartrate-Resistant Acid Phosphatase 5b (TRAP5b) at End of Treatment Cycle 3

Potential effects on bone was monitored by biomarkers of bone resorption and formation. Bone resorption was determined by assessing TRAP5b level. Screening (Visit 1) was defined as the last measurement before study drug administration.

Time frame:
Screening visit (Day -84) and end of Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · units per liter
Mean Change From Screening in Tartrate-Resistant Acid Phosphatase 5b (TRAP5b) at End of Treatment Cycle 3
units per literPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Mean Change From Screening in Tartrate-Resistant Acid Phosphatase 5b (TRAP5b) at End of Treatment Cycle 3-0.1 ± 0.56-0.4 ± 1.04-0.3 ± 0.56-0.4 ± 0.96
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities

Blood samples were collected to determine the clinical laboratory abnormalities. The laboratory assessments included chemistry, hematology and urinalysis.

Time frame:
From the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities
ParticipantsPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Activated partial thromboplastin time prolonged0010
Alanine aminotransferase increased0010
Aspartate aminotransferase increased0010
Gamma-glutamyltransferase increased1110
Blood triglycerides increased0010
Blood testosterone free increased0001
Blood testosterone increased0001
Hepatic enzyme increased0001
Hyperlipidaemia0001
Methaemoglobinaemia0013
SecondaryMean Change From Baseline Cycle in Sum of Days on Period at Treatment Cycles 1, 2 and 3

Participants recorded the presence of bleeding or spotting daily in the eDiary. The daily questions to assess bleeding pattern in the eDiary were "1a: During the past 24 hours, did you have any vaginal bleeding or spotting? If the response is "Yes", then the next question is, "1b: During the past 24 hours, have you been on your period?". Baseline cycle started at the start of menses associated with Visit 3 and ended at the day before the start of menses associated with Visit 4, or the day of Visit 4, whichever comes first.

Time frame:
Baseline Cycle (up to Day -28) and Treatment Cycles 1 (Day 32), 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · days
Mean Change From Baseline Cycle in Sum of Days on Period at Treatment Cycles 1, 2 and 3
daysPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Treatment Cycle 1-0.1 ± 1.47-0.3 ± 1.87-0.2 ± 1.850.2 ± 2.50
Treatment Cycle 2-0.3 ± 1.64-0.2 ± 2.33-0.3 ± 1.55-0.5 ± 2.59
Treatment Cycle 3-0.3 ± 1.82-0.7 ± 1.93-0.8 ± 2.32-0.6 ± 2.32
SecondaryNumber of Participants With Clinically Significant Electrocardiogram (ECG) Parameters Abnormalities

Triplicate standard 12-lead ECGs was obtained after the participant was in supine position for at least 5 minutes. The ECG measurements was summarized by taking the average of the available assessments. Only clinically significant ECG abnormalities are reported.

Time frame:
From the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Parameters Abnormalities
ParticipantsPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Electrocardiogram QT prolonged2102
Electrocardiogram T wave abnormal1000
SecondaryMean Change From Screening in Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3

Blood samples were collected to determine the serum level of LH and FSH. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.

Time frame:
Screening visit (Day -84) and 7 days after urine LH surge, end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · international units per liter
Mean Change From Screening in Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3
international units per literPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
LH: 7 days after urine LH surge-0.0 ± 9.23-0.6 ± 8.33-1.5 ± 7.052.3 ± 19.52
LH: end of Treatment Cycle 2-0.1 ± 8.17-0.6 ± 4.511.4 ± 9.49-0.1 ± 5.55
LH: end of Treatment Cycle 31.4 ± 13.172.0 ± 9.630.4 ± 8.921.6 ± 7.27
FSH: 7 days after urine LH surge-0.1 ± 15.04-3.2 ± 5.63-3.9 ± 6.75-3.8 ± 10.80
FSH: end of Treatment Cycle 20.6 ± 12.21-0.4 ± 5.971.2 ± 10.87-0.5 ± 17.71
FSH: end of Treatment Cycle 32.5 ± 18.861.3 ± 9.64-1.2 ± 8.101.2 ± 18.47
SecondaryMean Change From Screening in Estrone (E1) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3

Blood samples were collected to determine the serum level of E1. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.

Time frame:
Screening visit (Day -84) and 7 days after urine LH surge, end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · picogram per mL
Mean Change From Screening in Estrone (E1) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3
picogram per mLPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
7 days after urine LH surge-7.8 ± 141.7641.5 ± 185.6325.6 ± 63.9151.9 ± 209.01
End of Treatment Cycle 2-28.1 ± 136.7550.5 ± 379.65-7.0 ± 62.03-17.1 ± 111.62
End of Treatment Cycle 3-25.5 ± 144.2747.1 ± 354.49-3.9 ± 46.75-3.8 ± 136.91
SecondaryMean Change From Screening in Progesterone, Testosterone and Dehydroepiandrosterone (DHEA) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3

Blood samples were collected to determine the serum level of progesterone, testosterone and DHEA. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.

Time frame:
Screening visit (Day -84) and 7 days after urine LH surge, end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · nanomoles per liter
Mean Change From Screening in Progesterone, Testosterone and Dehydroepiandrosterone (DHEA) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3
nanomoles per literPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Progesterone: 7 days after urine LH surge11.5 ± 19.4914.8 ± 20.8217.7 ± 21.2311.9 ± 26.11
Progesterone: End of Treatment Cycle 2-0.8 ± 8.510.2 ± 9.480.2 ± 10.66-2.2 ± 14.58
Progesterone: End of Treatment Cycle 3-0.4 ± 10.331.1 ± 8.242.1 ± 16.14-1.9 ± 14.19
Testosterone: 7 days after urine LH surge-0.0 ± 0.340.0 ± 0.360.0 ± 0.330.1 ± 1.07
Testosterone: End of Treatment Cycle 20.0 ± 0.37-0.0 ± 0.37-0.0 ± 0.33-0.0 ± 0.28
Testosterone: End of Treatment Cycle 3-0.0 ± 0.330.1 ± 0.450.0 ± 0.28-0.0 ± 0.27
DHEA: 7 days after urine LH surge-1.2 ± 6.80-0.2 ± 7.29-1.6 ± 8.891.3 ± 7.50
DHEA: End of Treatment Cycle 20.5 ± 9.86-0.0 ± 6.65-1.3 ± 8.342.2 ± 8.36
DHEA: End of Treatment Cycle 3-0.0 ± 7.120.4 ± 6.65-0.5 ± 8.072.5 ± 13.25
SecondaryMean Change From Screening in Free Testosterone and Estradiol (E2) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3

Blood samples were collected to determine the serum level of free testosterone and E2. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.

Time frame:
Screening visit (Day -84) and 7 days after urine LH surge, end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · picomoles per liter
Mean Change From Screening in Free Testosterone and Estradiol (E2) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3
picomoles per literPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Free Testosterone: 7 days after urine LH surge0.1 ± 4.850.8 ± 5.360.4 ± 4.301.8 ± 9.93
Free Testosterone: End of Treatment Cycle 20.1 ± 4.940.4 ± 5.500.7 ± 3.920.4 ± 3.17
Free Testosterone: End of Treatment Cycle 30.1 ± 4.500.6 ± 4.620.9 ± 3.590.6 ± 3.51
E2: 7 days after urine LH surge-10.6 ± 693.7274.4 ± 424.18134.1 ± 385.35180.3 ± 301.65
E2: End of Treatment Cycle 2-76.5 ± 676.83-11.9 ± 423.167.8 ± 384.1165.6 ± 370.86
E2: End of Treatment Cycle 3-104.0 ± 734.4921.8 ± 432.5759.7 ± 368.9452.3 ± 317.51
SecondaryMean Change From Screening in Dehydroepiandrosterone Sulfate (DHEAS) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3

Blood samples were collected to determine the serum level of DHEAS. The LH surge was determined with urine LH kit at home. Screening (Visit 1) was defined as the last measurement before study drug administration.

Time frame:
Screening visit (Day -84) and 7 days after urine LH surge, end of Treatment Cycles 2 (Day 64) and 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
Reported as:
Mean · micromoles per liter
Mean Change From Screening in Dehydroepiandrosterone Sulfate (DHEAS) at 7 Days After Urine Luteinizing Hormone Surge and End of Treatment Cycles 2 and 3
micromoles per literPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
7 days after urine LH surge0.2 ± 1.730.1 ± 1.480.5 ± 1.830.5 ± 1.61
End of Treatment Cycle 20.2 ± 1.59-0.0 ± 1.260.4 ± 1.880.4 ± 1.59
End of Treatment Cycle 30.3 ± 1.63-0.0 ± 1.460.4 ± 1.500.4 ± 1.76
SecondaryPlasma Concentrations of OG-6219 and FOR-1011

Blood samples were collected to determine plasma concentration of OG-6219 and FOR-1011. The plasma concentration of OG-6219 and FOR-1011 was analyzed using an appropriate validated bioanalytical method.

Time frame:
Pre-witness dose and 1.5 hours postdose on start of Treatment Cycle 1 (Day 1), at 7 days after urine LH surge, and end of Treatment Cycle 2; Pre-witness dose on end of Treatment Cycle 3
Reported as:
Mean · ng/mL
Plasma Concentrations of OG-6219 and FOR-1011
ng/mLOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
OG-6219: start of Treatment Cycle 1: Pre-witness dose0.977 ± 8.68608.035 ± 56.52205.360 ± 49.7109
OG-6219: start of Treatment Cycle 1: 1.5 hours postdose190.754 ± 111.7670356.706 ± 214.6828610.430 ± 347.2826
OG-6219: 7 days after urine LH surge: Pre-witness dose41.467 ± 42.1563154.748 ± 181.5646159.431 ± 177.0591
OG-6219: 7 days after urine LH surge: 1.5 hours postdose220.459 ± 115.9525456.157 ± 231.4797727.633 ± 378.6709
OG-6219: end of Treatment Cycle 2: Pre-witness dose45.379 ± 50.961596.369 ± 97.4646144.031 ± 125.8066
OG-6219: end of Treatment Cycle 2: 1.5 hours postdose220.166 ± 130.5234454.316 ± 273.4854698.483 ± 424.0240
OG-6219: end of Treatment Cycle 3: Pre-witness dose46.249 ± 45.4428102.244 ± 121.2036134.696 ± 129.7118
FOR-1011: start of Treatment Cycle 1: Pre-witness dose1.140 ± 10.45266.314 ± 48.35852.488 ± 23.0762
FOR-1011: start of Treatment Cycle 1: 1.5 hours postdose113.709 ± 120.1908227.374 ± 168.6837367.034 ± 289.7623
FOR-1011: 7 days after urine LH surge: Pre-witness dose95.390 ± 73.7511322.026 ± 235.8709429.356 ± 263.5069
FOR-1011: 7 days after urine LH surge: 1.5 hours postdose219.654 ± 133.2333579.185 ± 309.3082933.811 ± 540.2559
FOR-1011: end of Treatment Cycle 2: Pre-witness dose94.372 ± 69.6035245.359 ± 175.9825415.913 ± 254.7596
FOR-1011: end of Treatment Cycle 2: 1.5 hours postdose212.727 ± 129.1773503.827 ± 312.9332777.500 ± 426.8007
FOR-1011: end of Treatment Cycle 3: Pre-witness dose90.638 ± 75.9499246.690 ± 191.3304367.871 ± 279.6791
SecondaryMaximum Concentration (Cmax) of OG-6219 and FOR-1011

Blood samples were collected to determine Cmax of OG-6219 and FOR-1011. The Cmax of OG-6219 and FOR-1011 was calculated using non-compartmental method. NCA= Noncompartmental analysis.

Time frame:
Pre-witness dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose on start of Treatment Cycle 1 (Day 1) and at 7 days after urine LH surge
Reported as:
Mean · ng/mL
Maximum Concentration (Cmax) of OG-6219 and FOR-1011
ng/mLOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
OG-6219: start of Treatment Cycle 1328.000 ± 187.7640344.500 ± 19.0919—
OG-6219: 7 days after urine LH surge227.000 ± 37.7536560.000 ± 76.3675—
FOR-1011: start of Treatment Cycle 1142.000 ± 48.4493149.000 ± 26.8701—
FOR-1011: 7 days after urine LH surge179.250 ± 63.5997801.500 ± 276.4788—
SecondaryTime Taken to Reach the Maximum Concentration (Tmax) of OG-6219 and FOR-1011

Blood samples were collected to determine tmax of OG-6219 and FOR-1011. The tmax of OG-6219 and FOR-1011 was calculated using non-compartmental method.

Time frame:
Pre-witness dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose on start of Treatment Cycle 1 (Day 1) and at 7 days after urine LH surge
Reported as:
Median · hour
Time Taken to Reach the Maximum Concentration (Tmax) of OG-6219 and FOR-1011
hourOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
OG-6219: start of Treatment Cycle 12.0000 (2.000 to 2.500)2.4900 (0.980 to 4.000)—
OG-6219: 7 days after urine LH surge1.2500 (0.980 to 2.000)2.0100 (1.500 to 2.520)—
FOR-1011: start of Treatment Cycle 12.5000 (2.500 to 2.970)3.5100 (3.020 to 4.000)—
FOR-1011: 7 days after urine LH surge2.0000 (1.530 to 2.500)2.7600 (2.520 to 3.000)—
SecondaryArea Under the Plasma Concentration-Time Curve During a Dosing Interval (AUCtau) of OG-6219 and FOR-1011

Blood samples were collected to determine AUCtau of OG-6219 and FOR-1011. The AUCtau of OG-6219 and FOR-1011 was calculated using non-compartmental method.

Time frame:
Pre-witness dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose on start of Treatment Cycle 1 (Day 1) and at 7 days after urine LH surge
Reported as:
Mean · hour*ng/mL
Area Under the Plasma Concentration-Time Curve During a Dosing Interval (AUCtau) of OG-6219 and FOR-1011
hour*ng/mLOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
OG-6219: start of Treatment Cycle 11049.827 ± 480.07261838.584 ± 339.6732—
OG-6219: 7 days after urine LH surge1259.562 ± 459.81913554.051 ± 97.8206—
FOR-1011: start of Treatment Cycle 1679.947 ± 110.4275993.293 ± 120.8272—
FOR-1011: 7 days after urine LH surge1342.994 ± 566.41435807.653 ± 1512.6682—

Adverse events

Collected over TEAEs are reported from the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/88 (0%)0/88 (0%)45/88 (51.1%)
OG-6219 50 mg0/88 (0%)1/88 (1.1%)46/88 (52.3%)
OG-6219 100 mg0/88 (0%)0/88 (0%)45/88 (51.1%)
OG-6219 150 mg0/89 (0%)0/89 (0%)49/89 (55.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
Abdominal painGastrointestinal disorders0/881/880/880/89
Most frequent other events
Showing 10 of 108
Most frequent other events
EventPlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mg
HeadacheNervous system disorders13/8815/8822/8818/89
Upper respiratory tract infectionInfections and infestations10/8810/884/887/89
NasopharyngitisInfections and infestations6/881/882/883/89
RhinitisInfections and infestations1/880/885/881/89
NauseaGastrointestinal disorders4/882/883/880/89
Urinary tract infectionInfections and infestations1/884/882/881/89
InfluenzaInfections and infestations1/884/881/881/89
DiarrhoeaGastrointestinal disorders2/883/881/883/89
DizzinessNervous system disorders3/880/882/882/89
EndometriosisReproductive system and breast disorders1/883/882/882/89

Baseline characteristics

Full analysis set included all randomized participants.

Age, Categorical
Age, Categorical(Participants)PlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mgTotal
<=18 years00000
Between 18 and 65 years88898889354
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mgTotal
Female88898889354
Male00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mgTotal
Black or African American20114
White83868687342
Multiple10102
Unknown12003
Not Reported11013
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mgTotal
Hispanic or Latino570113
Not Hispanic or Latino82818886337
Unknown00011
Not Reported11013
Region of Enrollment
Region of Enrollment(Participants)PlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mgTotal
Belgium42309
Bulgaria625215
Czechia534618
France11013
Germany21003
Hungary341210
Italy01012
Latvia132410
Poland58656366252
Sweden21205
United States668727
Overall Pelvic Pain (OPP) Score
Overall Pelvic Pain (OPP) Score(score on a scale)PlaceboOG-6219 50 mgOG-6219 100 mgOG-6219 150 mgTotal
Mean5.6 ± 1.516.0 ± 1.565.7 ± 1.675.8 ± 1.695.8 ± 1.61
08

Study locations

86 sites
  • Central Research Associates LLC dba Flourish Research
    Birmingham, Alabama 35205, United States
  • UAB Center for Women's Reproductive Health
    Birmingham, Alabama 35233, United States
  • Olympia Clinical Trials
    Los Angeles, California 90036, United States
  • Yale Fertility Center
    Orange, Connecticut 06477, United States
  • Physician Care Clinical Research, LLC
    Sarasota, Florida 34239, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • MediSense Inc
    Atlanta, Georgia 30363, United States
  • Paramount Research Solutions
    College Park, Georgia 30349, United States
  • Infinite Clinical Trials
    Morrow, Georgia 30260, United States
  • The Advanced Gynecologic Surgery Institute
    Park Ridge, Illinois 60068, United States
  • Ochsner Health Center - Baptist McFarland Medical Plaza
    New Orleans, Louisiana 70115, United States
  • Omni Fertility and Laser Institute
    Shreveport, Louisiana 71118, United States
  • John Hopkins University
    Baltimore, Maryland 21205, United States
  • Bosque Women's Care
    Albuquerque, New Mexico 87109, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267-0502, United States
  • Centricity Research Dublin
    Dublin, Ohio 43016, United States
  • Penn State Health Women's Health Clinic
    Hershey, Pennsylvania 17033, United States
  • Clinical Research of Philadelphia, LLC
    Philadelphia, Pennsylvania 19114, United States
  • Palmetto Clinical Research
    Summerville, South Carolina 29485, United States
  • Chattanooga Medical Research, LLC
    Chattanooga, Tennessee 37404, United States
  • Cedar Health Research, LLC
    Euless, Texas 76040, United States
  • The Women's Hospital of Texas
    Houston, Texas 77024, United States
  • Clinical Trial Network LLC
    Houston, Texas 77074, United States
  • Northeast Clinical Research of San Antonio
    San Antonio, Texas 78233, United States
  • Wasatch Clinical Research
    Salt Lake City, Utah 84107, United States
  • Tidewater Clinical Research
    Norfolk, Virginia 23502, United States
  • Seattle Women's: Health, Research, Gynecology
    Seattle, Washington 98105, United States
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • AZ Jan Palfijn Gent
    Ghent, 9000, Belgium
  • Universitair Ziekenhuis Ghent
    Ghent, 9000, Belgium
  • Jessa Ziekenhuis Hospital
    Hasselt, 3500, Belgium
  • CHU de Tivoli
    La Louvière, 7100, Belgium
  • Medical Center Repromed EOOD
    Pleven, 5800, Bulgaria
  • UMHAT "Sv. Georgi", EAD
    Plovdiv, 4002, Bulgaria
  • DCC " Ascendent" EAD
    Sofia, 1202, Bulgaria
  • SHATOD - Sofia District, EOOD
    Sofia, 1233, Bulgaria
  • MHAT for women's health - Nadezhda, OOD
    Sofia, 1330, Bulgaria
  • DCC "Alexandrovska", EOOD
    Sofia, 1431, Bulgaria
  • Medical Center Hera EOOD
    Sofia, 1510, Bulgaria
  • Group practice for specialized medical care in the field of obstetrics and gynecology - Gin Art OOD
    Sofia, 1606, Bulgaria
  • MHAT NiaMed OOD
    Stara Zagora, 6000, Bulgaria
  • Acibadem City Clinic MC Varna EOOD
    Varna, 9002, Bulgaria
  • Fakultni nemocnice Brno
    Brno, 602 00, Czechia
  • Fertimed s.r.o.
    Olomouc, 77900, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Prague, 100 34, Czechia
  • Femina Sana s.r.o.
    Prague, 130 00, Czechia
  • Ustav pro peci o matku a dite
    Prague, 147 10, Czechia
  • Hopital Saint Joseph Paris
    Paris, Paris 75674, France
  • Hôpital Cochin
    Paris, 75014, France
  • Hopital Tenon
    Paris, 75020, France
  • Hospital of Hautepierre
    Strasbourg, 67200, France
  • Universitaetsklinikum Duesseldorf AoeR
    Düsseldorf, North Rhine-Westphalia 40225, Germany
  • Charité - Campus Benjamin Franklin
    Berlin, 13353, Germany
  • Universitätsklinikum des Saarlandes
    Homburg, D-66421, Germany
  • Clinexpert Kft.
    Budapest, 1033, Hungary
  • Semmelweis Egyetem
    Budapest, 1082, Hungary
  • Szent Anna Maganrendelo
    Debrecen, 4024, Hungary
  • Somogy Varmegyei Kaposi Mor Oktato Korhaz
    Kaposvár, 7400, Hungary
  • Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz
    Nyíregyháza, 4400, Hungary
  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
    Seriate, Milano 20122, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Rome, Roma 168, Italy
  • Università di Cagliari-Presidio Policlinico Monserrato
    Monserrato, 09042, Italy
  • University of Siena Policlinico
    Siena, 53100, Italy
  • Centro Ricerche Cliniche di Verona s.r.l.
    Verona, 37134, Italy
  • Latvian Maritime Medical Centre
    Riga, LV-1005, Latvia
  • Vitols & Vitols, Ltd.
    Riga, LV-1006, Latvia
  • Dr. Vasaraudze's Private Clinic
    Riga, LV-1011, Latvia
  • Przychodnia Wielospecjalistyczna Sk-Medica Spółka Z O.O.
    Wroclaw, Dolnoslask 54-034, Poland
  • Specjalistyczna Poradnia Ginekologiczna Janusz Tomaszewski Spółka Komandytowa
    Bialystok, 15-224, Poland
  • Klinika Leczenia Niepłodności, Ginekologii i Położnictwa Bocian
    Bialystok, 15-267, Poland
  • Klinika Leczenia Niepłodności, Ginekologii i Położnictwa Bocian
    Katowice, 40-081, Poland
  • Clinical Medical Research Sp. z o.o.
    Katowice, 40-156, Poland
  • NZOZ Medem
    Katowice, 40-301, Poland
  • Centra Medyczne Medyceusz
    Lodz, 91-053, Poland
  • Specjalistyczny Gabinet Ginekologiczno-Położniczy
    Lublin, 20-064, Poland
  • Centrum Medyczne Chodzki HLK
    Lublin, 20-093, Poland
  • KO-MED Centra Kliniczne Lublin II
    Lublin, 20-362, Poland
  • ETYKA Osrodek Badan Klinicznych
    Olsztyn, 10-117, Poland
  • Etg Siedlce
    Siedlce, 08-110, Poland
  • Klinika Leczenia Niepłodności, Ginekologii i Położnictwa Bocian
    Szczecin, 70-225, Poland
  • MICS Centrum Medyczne Torun
    Torun, 87-100, Poland
  • Specjalistyczna Praktyka Lekar
    Warsaw, 00-144, Poland
  • PRATIA S.A. MTZ Clinical Research Powered by Pratia
    Warsaw, 02-172, Poland
  • WIM Panstwowy Instytut Badawczy Centralny Szpital Kliniczny MON
    Warsaw, 04-141, Poland
  • Karolinska University Hospital
    Stockholm, 17176, Sweden
  • Danderyd Sjukhus
    Stockholm, 182 88, Sweden
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in May 2025, 31 months.

Results were first posted in May 2026, 11 months after primary completion.

Of 44 phase 2 interventional studies under Endometriosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 37. This study's 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2022
First posted
Sep 29, 2022
StartActual
Oct 25, 2022
Primary completionActual
May 28, 2025
CompletionActual
May 28, 2025
Results first posted
May 8, 2026
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05560646
Lead sponsor
Organon and Co
Collaborators
IQVIA Pty Ltd
Responsible party
Sponsor
First posted
Sep 29, 2022
Start date
Oct 25, 2022
Primary completion
May 28, 2025
Completion
May 28, 2025
Results posted
May 8, 2026
Last update
May 8, 2026

Study contacts

Clinical Lead Late-Stage Clinical Development
study director · Organon and Co

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linustedastat

Start the discussion